title: Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease--relation to plasma concentration.
abstract: The hemodynamic and antiischemic effects of a 150-mg single oral dose of the PDE inhibitor enoximone were correlated with the plasma levels of enoximone and its sulfoxide metabolite. Twenty-one patients with angiographically documented coronary artery disease were investigated by exercise testing 1 and 2 hours after drug administration. The control group consisted of 15 patients with proven coronary artery disease and stable reproducible angina pectoris on exercise. The enoximone group included 14 responders with therapeutic plasma concentrations 2 hours after drug intake and significantly reduced mean pulmonary artery pressures on exercise (from 42.4 +/- 8.6 to 30.9 +/- 11.2 mmHg, p less than 0.05). Compared to basal exercise values, responders showed a reduced ST-segment depression by 1 hour after drug intake (2.1 +/- 1.2 vs. 1.3 +/- 3 mm, p less than 0.05) and minimal values after 2 hours (0.9 +/- 1.0 mm, p less than 0.01) at comparable workloads. There were no significant changes in heart rate, blood pressure, cardiac output, and systemic vascular resistance. No significant improvement in the hemodynamic parameters and ST-segment depression was found in nonresponders with plasma concentrations below 100 ng/ml and 500 mg/ml for enoximone and its metabolite, respectively. In summary, oral administration of enoximone in patients with coronary artery disease led to favorable acute hemodynamic and antiischemic effects at sufficiently high plasma levels of enoximone and its sulfoxide metabolite.
authors.affiliation: Kerckhoff-Klinik of the Max-Planck Society, Bad Nauheim, FRG.
authors.forename: V
authors.initials: V
authors.lastname: Mitrovic
authors.forename: O
authors.initials: O
authors.lastname: Petrovic
authors.forename: H
authors.initials: H
authors.lastname: Bahavar
authors.forename: J
authors.initials: J
authors.lastname: Neuzner
authors.forename: H A
authors.initials: HA
authors.lastname: Dieterich
authors.forename: M
authors.initials: M
authors.lastname: Schlepper
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy*; D004562:Electrocardiography / Q000187:drug effects; D017335:Enoximone; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D017335:Enoximone